Welcome to our dedicated page for Day One Biopharmaceuticals SEC filings (Ticker: DAWN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Day One Biopharmaceuticals filings document the company's transition from a Nasdaq-listed oncology biopharmaceutical issuer to an acquired company with Exchange Act deregistration filings. The record includes Form 25 removal of DAWN common stock from Nasdaq and Form 15 certification covering termination of registration or suspension of reporting duties after the acquisition.
Day One's 8-K filings report material agreements, tender-offer and merger-related events, shareholder voting and governance matters, capital-structure disclosures, and financial-statement exhibits. Other disclosures cover OJEMDA (tovorafenib), U.S. product revenue reporting, Ipsen's ex-U.S. commercialization rights, and clinical or regulatory updates for pediatric low-grade glioma and rare-cancer programs.
Day One Biopharmaceuticals, Inc. has been acquired by Servier in an all-cash deal. A Servier subsidiary completed a tender offer to buy all outstanding Day One common shares at $21.50 per share, followed by a merger under Delaware law.
At the offer’s expiration on April 22, 2026, a total of 88,180,910 shares, or about 85.34% of shares then outstanding, were validly tendered, satisfying the minimum tender condition. Remaining shares were converted into the right to receive the same cash price, and Day One became a wholly owned subsidiary of Servier.
The transaction values Day One at approximately $2.5 billion in equity value, funded with Servier and Parent cash and similar instruments. Day One’s stock will be delisted from Nasdaq, SEC registration will be terminated, equity incentive plans and the ESPP have been cancelled, and former directors and officers have been replaced by Servier designees.
Day One Biopharmaceuticals amended its Schedule 14D-9 to report that the cash Offer at $21.50 per share expired on April 22, 2026, with 88,180,910 Shares validly tendered, representing approximately 85.34% of issued and outstanding shares at the Expiration Time.
The Purchaser accepted for payment those tendered Shares and on April 23, 2026 the merger closed under Section 251(h) of the DGCL, making Day One a wholly owned subsidiary of Parent. Trading in the Shares ceased on Nasdaq prior to April 23, 2026, and the company and Parent intend to delist, deregister and suspend reporting by filing Form 25 and Form 15 as promptly as practicable.
Day One Biopharmaceuticals was acquired by Servier through a tender offer and merger. The Offer expired at one minute past 11:59 p.m. Eastern on April 22, 2026, and 88,180,910 Shares, representing approximately 85.34% of issued and outstanding shares as of the Expiration Time, were validly tendered and not properly withdrawn. Purchaser accepted for payment those tendered shares and completed the merger on April 23, 2026 under Section 251(h) of the DGCL, making the Company a wholly owned subsidiary of Parent. At the Effective Time, each non‑tendered issued and outstanding share (other than shares subject to appraisal or owned by the parties) was converted into the right to receive the Offer Price. Trading in the Shares ceased on Nasdaq prior to trading on April 23, 2026, and Parent requested delisting/deregistration actions including filing Form 25 and an intention to file Form 15 to terminate registration and suspend reporting obligations.
Day One Biopharmaceuticals, Inc. filed an amendment to its annual report to add Part II and Part III information, including market, governance and detailed executive compensation disclosures. The company notes a previously announced agreement for Servier Pharmaceuticals LLC to acquire Day One via a merger, after which Day One will become a wholly owned subsidiary.
The filing outlines board composition, committee memberships and independence, and confirms adoption of an insider trading policy, code of business conduct, and a Dodd-Frank–compliant clawback policy. For 2025, the compensation committee targeted pay heavily toward performance, with about 89% of CEO target pay and 82% for other named executives in variable, at-risk compensation.
Annual cash bonuses were tied to financial, clinical and corporate goals, with a 2025 company performance multiplier of 110%, resulting in above-target payouts. The amendment also describes a 2025 repricing of certain underwater employee and director stock options to an exercise price of $8.99, intended to enhance retention without issuing significant additional equity or cash.
Day One Biopharmaceuticals amends its Schedule 14D-9 to revise Centerview Partners’ valuation analyses and to add disclosures about related shareholder litigation. The filing restates selected public-company and precedent-transaction multiples, updates a DCF and management projections, and discloses two complaints and additional demand letters concerning the proposed merger.
The amendment compares Centerview’s implied equity ranges of $11.80 to $20.00 and $17.25 to $25.40 per share to the $21.50 per-share offer. It also cites Day One’s projected $645M 2029 risk-adjusted revenue, estimated net cash of $314M, and a fully-diluted share base of approximately 103.3 million shares (with ~15.3 million options, 3.7 million RSUs and 0.8 million pre-funded warrants).
AI Day1 LLC and its affiliates updated their ownership filing on Day One Biopharmaceuticals after tendering their entire stake into a cash buyout offer. On April 9, 2026, AI Day1 tendered 12,929,322 shares of Common Stock to Servier Detroit Inc.’s tender offer at $21.50 per share in cash.
The reporting group’s stake represented 12.52% of Day One’s Common Stock, based on 103,297,691 shares outstanding as of February 19, 2026. AI Day1 also directly holds warrants to purchase 827,586 additional shares, which may be deemed beneficially owned indirectly by Access Industries Holdings LLC, Access Industries Management, LLC and Len Blavatnik, although each of them disclaims beneficial ownership.
Servier S.A.S. and its subsidiaries amended the Schedule TO to report that the FTC granted early termination of the HSR waiting period, effective April 7, 2026 at 1:37 p.m. Eastern Time. This satisfies the HSR condition listed in Section 15 of the offer.
The tender offer for all outstanding shares of Day One Biopharmaceuticals, Inc. remains subject to the Offer's other conditions set forth in Section 15. The amendment supplements Item 11 (Certain Legal Matters; Regulatory Approvals) and otherwise leaves the Schedule TO unchanged.
Day One Biopharmaceuticals amended its Schedule 14D-9 to report that the premerger waiting period under the Hart‑Scott‑Rodino Act was terminated early by the FTC on April 7, 2026 at 1:37 p.m. Eastern Time. The company confirms the HSR condition to the cash tender offer at $21.50 per share has been satisfied; the Offer remains subject to the other conditions set forth in the Offer to Purchase.
Day One Biopharmaceuticals Inc. Schedule 13G/A reports that FMR LLC (with Abigail P. Johnson listed) beneficially owns 23,639.69 shares of common stock, representing 0.0% of the class as reported. The filing is an amendment and is signed under powers of attorney dated in 2023.